Oncoinvent Advances Radspherin[®] to Third Dose Level in Ongoing Phase 1 Clinical Trial
Safety review of second dose-level cohort allows study to advance to third cohort of colorectal cancer patients with peritoneal carcinomatosis in Radspherin[®] clinical trial.Oslo 30. October 2020 Oncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisotope-based therapies announced today that the trial Safety Monitoring Committee overseeing the first-in-human Phase 1 clinical study of Radspherin[®] in colorectal cancer patients suffering from peritoneal carcinomatosis have approved the advancement of the study to the third level dosing cohort.Jan A. Alfheim,